The future of Alzheimer’s disease: blood biomarkers, brain imaging, and screening the cognitively unimpaired

What will Alzheimer’s disease diagnosis look like in 5–10 years?

In this episode of In Conversation With…, Laura Hart is joined by the authors behind The Lancet Neurology Series on Future Directions in Alzheimer’s Disease and Related Disorders: Clifford Jack (Mayo Clinic), Charlotte Teunissen (Amsterdam UMC), Tammie Benzinger (Washington University in St Louis), and Jonathan Graff-Radford (Mayo Clinic). They discuss blood-based biomarkers and plasma p-tau217 testing, amyloid PET and MRI monitoring for ARIA, anti-amyloid therapies, and what it means to screen cognitively unimpaired people for Alzheimer’s disease neuropathological change. The conversation covers the role of primary care in early diagnosis, direct-to-consumer biomarker tests, how to communicate borderline results to healthy people, the AHEAD and TRAILBLAZER-ALZ prevention trials, and whether these pathways can work outside well-resourced health systems.

Click here to read the articles in the series:

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00246-2/fulltext

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00285-1/fulltext

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00248-6/fulltext